Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Purity:
97.00%
CAS Number:
[910649-32-0]
Target:
Interleukin|||IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
